Fig. 1 Potential factors that contribute to gender differences in antidepressant-induced mania

Competing interests: MGM has received consulting income and research funding from Janssen Pharmaceuticals. The remaining author declares that they have no conflict of interest.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Azorin JM, Belzeaux R, Kaladjian A, Adida M, Hantouche E, Lancrenon S, et al. Risks associated with gender differences in bipolar I disorder. *J Affect Disord.* 2013;151:1033–40.
2. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. *BMC Med.* 2012;10:148.
3. Saunders EF, Fernandez-Mendoza J, Kamali M, Assari S, McInnis MG. The effect of poor sleep quality on mood outcome differs between men and women: A longitudinal study of bipolar disorder. *J Affect Disord.* 2015;180: 90–6.
4. Scott J, Brichant-Petitjean C, Etain B, Henry C, Kahn JP, Azorin JM, et al. A re-examination of antidepressant treatment-emergent mania in bipolar disorders: evidence of gender differences. *Acta Psychiatr Scand.* 2017;135:479–88.
5. Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. *J Clin Psychiatry* 2018;79:17m11765.
6. Karanti A, Bobeck C, Osterman M, Kardell M, Tidemalm D, Runeson B, et al. Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients. *J Affect Disord.* 2015;174:303–9.

Guidance cues: linking drug use in adolescence with psychiatric disorders

Lauren M. Reynolds^{1,2} and Cecilia Flores²

Neuropsychopharmacology (2019) 44:225–226; <https://doi.org/10.1038/s41386-018-0221-7>

Adolescent onset of drug use is associated with an enduring elevation in the risk of progressing from recreational use to addiction. Unfortunately, adolescent experimentation with

drugs of abuse remains common, with more than half of initiates under the age of 18 years old. This peak age for drug initiation coincides with a critical developmental period for

¹Integrated Program in Neuroscience, McGill University, Montréal, QC, Canada and ²Department of Psychiatry and Department of Neurology and Neurosurgery, McGill University, Douglas Mental Health University Institute, Montréal, QC, Canada
Correspondence: Cecilia Flores (cecilia.flores@mcgill.ca)

Received: 24 July 2018 Accepted: 5 September 2018
Published online: 1 October 2018

reward-relevant substrates. Most notably, mesocorticolimbic dopamine circuitry is uniquely sensitive to disruption by drugs in adolescence, resulting in lasting behavioral changes linked to addiction vulnerability [1].

Our recent work in rodents highlights a novel role for guidance cues in (a) the adolescent establishment of mesocorticolimbic dopamine connectivity and cognitive processing and (b) the enduring effects of drugs of abuse on these events. First, we discovered that dopamine axons still grow to the prefrontal cortex (PFC) in adolescence [2]. This is the first concrete demonstration of long-distance axon growth in late postnatal development, which entails targeting decisions by dopamine axons en route to their final postsynaptic partners. Axon targeting relies on the interaction of extracellular guidance cues and their receptors. We find that the guidance cue Netrin-1 and its receptor DCC dictate dopamine axon targeting in adolescence. Specifically, mesolimbic dopamine axons have high levels of DCC and recognize the nucleus accumbens as their final target in adolescence. In contrast, mesocortical dopamine axons have little or no DCC and therefore fail to recognize this region as their final target and grow to the PFC instead. Reduced DCC expression in mesolimbic dopamine axons induces targeting errors in the nucleus accumbens and their ectopic growth to the PFC. By segregating dopamine innervation to cortical or non-cortical regions, DCC receptors organize PFC structure and function, including cognitive behaviors that are altered in addiction [2].

Second, we demonstrated that repeated non-contingent exposure to amphetamine in adolescence, at a dose resembling human recreational use, downregulates DCC expression in dopamine neurons [3]. This perfectly positions DCC signaling to mediate the enduring neuroanatomical and behavioral consequences of adolescent drug use. Indeed, amphetamine in early adolescence leads to an increase in the span of dopamine innervation to the PFC. However, it also leads to disorganized synaptic contacts and reduced dopamine turnover in adulthood [4, 5]. These alterations, in turn, produce deficits in behavioral inhibition and exaggerated salience attribution to drug-paired contexts; two behaviors associated with addiction susceptibility [4, 5].

Our findings indicate that DCC signaling wires the adolescent PFC and contributes to amphetamine-induced susceptibility to addiction. Interestingly, amphetamine

downregulates DCC via micro-RNAs, which are important biomarkers and mediators of psychiatric conditions [3]. Furthermore, variations in DCC expression occur in humans and lead to altered mesocorticolimbic connectivity [6]. Our work therefore contributes a novel perspective to the ongoing efforts of developing prevention and treatment strategies for addiction. The DCC pathway represents a promising site for targeted intervention during adolescence both to counteract detrimental effects of early drug use and promote healthy brain development.

FUNDING

This work was supported by the National Institute on Drug Abuse (R01DA037911 to C.F.; F31DA041188 to L.M.R.), the Canadian Institutes of Health Research (MOP-74709 to C.F.), and the Natural Sciences and Engineering Research Council of Canada (2982226 to C.F.). C.F. is a research scholar of the Fonds de Recherche du Québec - Santé. L.M.R. was supported by predoctoral fellowships from The Djavad Mowafaghian Foundation and Fulbright Canada. Competing interest: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Gulley JM, Juraska JM (2013). The effects of abused drugs on adolescent development of corticolimbic circuitry and behavior. *Neuroscience* <https://doi.org/10.1016/j.neuroscience.2013.05.026>.
2. Reynolds LM, Pokinko M, Torres-Berrio A, Cuesta S, Lambert LC, Del Cid-Pellitero E, et al. DCC receptors drive prefrontal cortex maturation by determining dopamine axon targeting in adolescence. *Biol Psychiatry*. 2018a;83:181–92.
3. Cuesta S, Restrepo-Lozano JM, Silvestrin S, Nouel D, Torres-Berrio A, Reynolds LM, et al. Non-contingent exposure to amphetamine in adolescence recruits miR-218 to regulate Dcc expression in the VTA. *Neuropsychopharmacology*. 2018;43:900–11.
4. Reynolds LM, Makowski CS, Yogendran SV, Kiessling S, Cermakian N, Flores C. Amphetamine in adolescence disrupts the development of medial prefrontal cortex dopamine connectivity in a dcc-dependent manner. *Neuropsychopharmacology*. 2015;40:1101–12.
5. Reynolds LM, Yetnikoff L, Pokinko M, Wodzinski M, Epelbaum JG, Lambert LC, et al. (2018b) Early adolescence is a critical period for the maturation of inhibitory behavior. *In Press, Cerebral Cortex*
6. Vosberg DE, Zhang Y, Menegaux A, Chalupa A, Manitt C, Zehntner S, et al. Mesocorticolimbic connectivity and volumetric alterations in DCC mutation carriers. *J Neurosci*. 2018;38:4655–4665.

The ventromedial prefrontal cortex: a putative locus for trait inattention

Matthew D. Albaugh¹ and Alexandra S. Potter¹

Neuropsychopharmacology (2019) 44:226–227; <https://doi.org/10.1038/s41386-018-0193-7>

Efforts to identify structural brain correlates of attention-deficit/hyperactivity disorder (ADHD) have yielded inconsistent results,

with no common structural biomarker emerging across studies. Methodological factors may obscure underlying brain-behavior

¹Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT, USA
Correspondence: Matthew D. Albaugh (malbaugh@uvm.edu)